# Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

> **NCT05186558** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 54 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Neoplasms by Histologic Type

## Interventions

- **DRUG:** penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

## Key facts

- **NCT ID:** NCT05186558
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-15
- **Primary completion:** 2024-01-15
- **Final completion:** 2026-02-15
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186558, "Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05186558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*